News

Amgen has revealed detailed results from the phase 3 181 trial evaluating Vectibix in combination with Folfiri, as a second-line treatment for metastatic colorectal cancer. In this trial,

SoBran has signed a multi-year contract to provide managerial and supervisory personnel for the University of Texas Southwestern Medical Center in Dallas, TX. Under this contract SoBran will

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, has received an additional order from the US Department of health and human services (HHS) to produce vaccine to

BioTime, has revealed its plan to organize a new subsidiary, BioTime Asia, for the purpose of clinically developing and marketing therapeutic stem cell products in the People’s Republic

Karnataka drug controller, Dr BR Jagashetty has asked to amend Drugs & Cosmetics Act to restrict the movement of not-of-standard quality and defective packaging drugs in the state.

Lundbeck, a wholly owned subsidiary of H Lundbeck in Denmark, has announced that Sabril (vigabatrin) tablets and powder for Oral Solution are now available for prescribing in the

AEterna Zentaris has announced the completion of a phase 1 study of orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma.

NovoStent has completed enrollment in the European clinical trial evaluating the use of SAMBATM Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease.

NanoViricides has signed a ‘Master Service Agreement’ with the Southern Research Institute (Southern Research), Birmingham. The agreement will allow Southern Research to perform testing of the company’s anti-Influenza